{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:37:19Z","timestamp":1793090239387,"version":"4.5.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004569","name":"Ministerstwo Edukacji i Nauki","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004569","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.critrevonc.2026.105528","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T15:23:13Z","timestamp":1786029793000},"page":"105528","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Cancer without a map: Navigating cancer of unknown primary through molecular profiling"],"prefix":"10.1016","volume":"227","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6575-8005","authenticated-orcid":false,"given":"Konrad","family":"Ta\u0142asiewicz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3447-7328","authenticated-orcid":false,"given":"Micha\u0142","family":"Mikula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4572-6641","authenticated-orcid":false,"given":"Aleksandra","family":"Kapa\u0142a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105528_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1274163","article-title":"Deciphering the origin and therapeutic targets of cancer of unknown primary: a case report that illustrates the power of integrative whole-exome and transcriptome sequencing analysis","volume":"13","author":"Al Assaad","year":"2024","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105528_bib2","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000867","article-title":"Entrectinib approval by EMA reinforces options for ROS1 and tumour agnostic NTRK targeted cancer therapies","volume":"5","author":"Ardini","year":"2020","journal-title":"ESMO Open."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105528_bib3","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1002\/ijc.32882","article-title":"Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary","volume":"146","author":"Bochtler","year":"2020","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105528_bib4","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.canep.2014.03.010","article-title":"Descriptive epidemiology of cancer of unknown primary site in Scotland, 1961\u20132010","volume":"38","author":"Brewster","year":"2014","journal-title":"Cancer Epidemiol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105528_bib5","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1053\/j.semdp.2020.12.001","article-title":"The role of molecular profiling in the diagnosis and management of metastatic undifferentiated cancer of unknown primary\u2606","volume":"38","author":"Dermawan","year":"2021","journal-title":"Semin. Diagn. Pathol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105528_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100407","article-title":"Site-specific therapy in cancers of unknown primary site: a systematic review and meta-analysis","volume":"7","author":"Ding","year":"2022","journal-title":"ESMO Open."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105528_bib7","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion\u2013positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105528_bib8","article-title":"Management and survival of patients with cancer of unknown primary discussed by a French national multidisciplinary tumour board: a retrospective analysis","volume":"60","author":"Dupain","year":"2026","journal-title":"Lancet Reg. Health Eur."},{"key":"10.1016\/j.critrevonc.2026.105528_bib9","doi-asserted-by":"crossref","first-page":"v851","DOI":"10.1093\/annonc\/mdz394","article-title":"A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04)","volume":"30","author":"Fizazi","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105528_bib10","doi-asserted-by":"crossref","first-page":"S1419","DOI":"10.1016\/j.annonc.2023.09.245","article-title":"MO36-2 Updated analysis from a phase II study on the efficacy of nivolumab in patients with cancer of unknown primary (NivoCUP)","volume":"34","author":"Funakoshi","year":"2023","journal-title":"Ann. Oncol."},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105528_bib11","doi-asserted-by":"crossref","first-page":"12440","DOI":"10.18632\/oncotarget.2574","article-title":"Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: Analysis of 1806 cases","volume":"5","author":"Gatalica","year":"2014","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105528_bib12","first-page":"111","article-title":"Healthcare costs before and after diagnosis of cancer of unknown primary versus ovarian cancer in Australia","volume":"7","author":"Gordon","year":"2023","journal-title":"Pharm. - Open."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105528_bib13","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1200\/JCO.2012.43.3755","article-title":"Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute","volume":"31","author":"Hainsworth","year":"2013","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105528_bib14","first-page":"112","article-title":"A retrospective study of treatment outcomes in patients with carcinoma of unknown primary site and a colorectal cancer molecular profile","volume":"11","author":"Hainsworth","year":"2012","journal-title":"Clin. Colorectal Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105528_bib15","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.clon.2018.06.012","article-title":"Site-specific chemotherapy based on predicted primary site by pathological profile for carcinoma of unknown primary site","volume":"30","author":"Hasegawa","year":"2018","journal-title":"Clin. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105528_bib16","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.18.00771","article-title":"Randomized phase II trial comparing site-specific treatment based on gene expression profiling with carboplatin and paclitaxel for patients with cancer of unknown primary site","volume":"37","author":"Hayashi","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105528_bib17","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/ijc.28969","article-title":"Smoking and body mass index as risk factors for subtypes of cancer of unknown primary: risk factors of CUP","volume":"136","author":"Hemminki","year":"2015","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105528_bib18","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/CEJ.0000000000000165","article-title":"Cancer of unknown primary is associated with diabetes","volume":"25","author":"Hemminki","year":"2016","journal-title":"Eur. J. Cancer Prev."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105528_bib19","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/ijc.27988","article-title":"Site-specific survival rates for cancer of unknown primary according to location of metastases","volume":"133","author":"Hemminki","year":"2013","journal-title":"Int. J. Cancer"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105528_bib20","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1002\/ijc.29657","article-title":"Risk of cancer of unknown primary after hospitalization for autoimmune diseases","volume":"137","author":"Hemminki","year":"2015","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105528_bib21","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41698-024-00648-0","article-title":"Metastatic renal cell carcinoma with occult primary: a multicenter prospective cohort","volume":"8","author":"Jacquin","year":"2024","journal-title":"Npj Precis. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105528_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-02543-1","article-title":"Real-world data analysis of patients with cancer of unknown primary","volume":"11","author":"Kang","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105528_bib23","unstructured":"Keytruda | European Medicines Agency (EMA). June 21, 2018. Accessed September 23, 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/keytruda."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105528_bib24","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.annonc.2022.11.013","article-title":"Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Kr\u00e4mer","year":"2023","journal-title":"Ann. Oncol."},{"issue":"10452","key":"10.1016\/j.critrevonc.2026.105528_bib25","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(24)00814-6","article-title":"Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study","volume":"404","author":"Kr\u00e4mer","year":"2024","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105528_bib26","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/cancers14143429","article-title":"New genetic technologies in diagnosis and treatment of cancer of unknown primary","volume":"14","author":"Krawczyk","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105528_bib27","article-title":"Molecularly directed therapy in cancers of unknown primary: a systematic review and meta-analysis","volume":"222","author":"Labaki","year":"2025","journal-title":"Eur. J. Cancer Oxf. Engl. 1990"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105528_bib28","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1002\/1878-0261.13026","article-title":"MicroRNA expression profiling with a droplet digital PCR assay enables molecular diagnosis and prognosis of cancers of unknown primary","volume":"15","author":"Laprovitera","year":"2021","journal-title":"Mol. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105528_bib29","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/bjc.2012.516","article-title":"Evaluation of survival benefits by platinums and taxanes for an unfavourable subset of carcinoma of unknown primary: a systematic review and meta-analysis","volume":"108","author":"Lee","year":"2013","journal-title":"Br. J. Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105528_bib30","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/S1470-2045(24)00313-9","article-title":"Site-specific therapy guided by a 90-gene expression assay versus empirical chemotherapy in patients with cancer of unknown primary (Fudan CUP-001): a randomised controlled trial","volume":"25","author":"Liu","year":"2024","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105528_bib31","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00117-013-2544-z","article-title":"CUP-syndrom: epidemiologie und pathogenese","volume":"54","author":"L\u00f6ffler","year":"2014","journal-title":"Radiologe"},{"issue":"28","key":"10.1016\/j.critrevonc.2026.105528_bib32","doi-asserted-by":"crossref","first-page":"44322","DOI":"10.18632\/oncotarget.10035","article-title":"Molecular driver alterations and their clinical relevance in cancer of unknown primary site","volume":"7","author":"L\u00f6ffler","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105528_bib33","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbae028","article-title":"New techniques to identify the tissue of origin for cancer of unknown primary in the era of precision medicine: progress and challenges","volume":"25","author":"Ma","year":"2024","journal-title":"Brief. Bioinform"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105528_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair\u2013deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.critrevonc.2026.105528_bib35","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105528_bib36","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2025-099134","article-title":"Impact of comprehensive genomic profiling and molecular tumour board on costs and access to tailored therapies: real-world observational study","volume":"15","author":"Micheli","year":"2025","journal-title":"BMJ Open."},{"key":"10.1016\/j.critrevonc.2026.105528_bib37","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1038\/s41467-022-31866-4","article-title":"Comprehensive genomic and epigenomic analysis in cancer of unknown primary guides molecularly-informed therapies despite heterogeneity","volume":"13","author":"M\u00f6hrmann","year":"2022","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105528_bib38","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S1470-2045(16)30297-2","article-title":"Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis","volume":"17","author":"Moran","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105528_bib39","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Occult Primary Accessed September 23, 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/occult.pdf."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105528_bib40","doi-asserted-by":"crossref","first-page":"e769","DOI":"10.1002\/onco.13744","article-title":"A challenging task: identifying patients with cancer of unknown primary (CUP) according to ESMO guidelines: the CUPISCO trial experience","volume":"26","author":"Pauli","year":"2021","journal-title":"Oncologist"},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105528_bib41","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1016\/S0959-8049(03)00547-1","article-title":"Diagnostic and therapeutic management of cancer of an unknown primary","volume":"39","author":"Pavlidis","year":"2003","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105528_bib42","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.critrevonc.2012.02.002","article-title":"Long-term survivors among patients with cancer of unknown primary","volume":"84","author":"Pavlidis","year":"2012","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105528_bib43","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/path.6022","article-title":"A comparison of DNA sequencing and gene expression profiling to assist tissue of origin diagnosis in cancer of unknown primary","volume":"259","author":"Posner","year":"2023","journal-title":"J. Pathol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105528_bib44","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/s41571-025-01060-8","article-title":"Rethinking cancer of unknown primary: from diagnostic challenge to targeted treatment","volume":"22","author":"Pouyiourou","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105528_bib45","doi-asserted-by":"crossref","first-page":"6761","DOI":"10.1038\/s41467-023-42400-5","article-title":"Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial","volume":"14","author":"Pouyiourou","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105528_bib46","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ejca.2021.08.019","article-title":"Local ablative treatment with surgery and\/or radiotherapy in single-site and oligometastatic carcinoma of unknown primary","volume":"157","author":"Pouyiourou","year":"2021","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105528_bib47","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1002\/cam4.4973","article-title":"Clinicopathological, molecular and prognostic characteristics of cancer of unknown primary in China: an analysis of 1420 cases","volume":"12","author":"Qi","year":"2023","journal-title":"Cancer Med."},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105528_bib48","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1056\/NEJMcp2402691","article-title":"Cancer of unknown primary site","volume":"392","author":"Raghav","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105528_bib49","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004822","article-title":"Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial","volume":"10","author":"Raghav","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105528_bib50","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1038\/s41467-025-59661-x","article-title":"Whole genome sequencing improves tissue-of-origin diagnosis and treatment options for cancer of unknown primary","volume":"16","author":"Rebello","year":"2025","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105528_bib51","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1080\/0284186X.2022.2098053","article-title":"Cost-effectiveness of molecularly matched off-label therapies for end-stage cancer \u2013 the MetAction precision medicine study","volume":"61","author":"Ree","year":"2022","journal-title":"Acta Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105528_bib52","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jamaoncol.2014.216","article-title":"Comprehensive genomic profiling of carcinoma of unknown primary site: new routes to targeted therapies","volume":"1","author":"Ross","year":"2015","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2026.105528_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.clon.2025.103944","article-title":"The use of molecular tools for identifying and guiding treatment of cancers of unknown primary: a systematic review","volume":"48","author":"Saibil","year":"2025","journal-title":"Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105528_bib54","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1038\/s41591-022-01931-y","article-title":"Pan-cancer efficacy of pralsetinib in patients with RET fusion\u2013positive solid tumors from the phase 1\/2 ARROW trial","volume":"28","author":"Subbiah","year":"2022","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105528_bib55","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105528_bib56","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.annonc.2021.11.009","article-title":"Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary","volume":"33","author":"Tanizaki","year":"2022","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105528_bib57","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1158\/1078-0432.CCR-10-2599","article-title":"Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary","volume":"17","author":"Varadhachary","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105528_bib58","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1186\/s12885-025-14778-6","article-title":"Clinical efficacy of immune checkpoint inhibitors for cancer of unknown primary: a multi-center retrospective study","volume":"25","author":"Wang","year":"2025","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105528_bib59","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13045-022-01362-9","article-title":"Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021","volume":"15","author":"Wu","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105528_bib60","doi-asserted-by":"crossref","first-page":"5686","DOI":"10.1038\/s41467-023-41015-0","article-title":"DNA methylation profiling to determine the primary sites of metastatic cancers using formalin-fixed paraffin-embedded tissues","volume":"14","author":"Zhang","year":"2023","journal-title":"Nat. Commun."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826004154?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826004154?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:02:32Z","timestamp":1793088152000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826004154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":60,"alternative-id":["S1040842826004154"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105528","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer without a map: Navigating cancer of unknown primary through molecular profiling","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105528","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105528"}}